又一款“全程一次用药”的国产流感口服药上市，张文宏团队牵头研发

Core Viewpoint - The approval of the oral antiviral drug Maraslavir (brand name: Jikeshou) by the National Medical Products Administration (NMPA) marks a significant advancement in the treatment of influenza, particularly for healthy adults with uncomplicated influenza A and B infections [1][2]. Group 1: Drug Approval and Characteristics - Maraslavir is a new generation polymerase acidic protein (PA) nuclease inhibitor with broad-spectrum antiviral properties against influenza A, B, and highly pathogenic avian influenza viruses [1]. - The drug was developed by a team led by Zhang Wenhong from the National Center for Infectious Disease Medicine and Huashan Hospital affiliated with Fudan University [1]. - Clinical data published in the journal "Clinical Microbiology and Infection" earlier this year supports the drug's efficacy and safety [1]. Group 2: Market Context and Comparisons - Maraslavir is positioned as a domestic alternative to the imported flu drug Baloxavir (brand name: Sufuda), which has raised concerns about supply shortages [2]. - Another domestic antiviral, Mashulavir (brand name: Yisuda), has also been approved for treating uncomplicated influenza in adolescents and adults [2]. - Pricing analysis shows that some newly launched domestic antiviral drugs are priced higher than their imported counterparts, with Mashulavir priced at approximately 320 yuan for 20mg*2 tablets, compared to Baloxavir's price of less than 200 yuan [2]. Group 3: Resistance and Clinical Use - Current clinical studies are addressing the resistance issues associated with existing antiviral drugs [2]. - Data indicates that Mashulavir has a low resistance mutation rate of 0.7% and 0.9% for influenza A H1N1 and H3N2 strains, respectively, with only one mutation site for H1N1 and no detected resistance mutations in influenza B patients [2].